Business
Soligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results
PRINCETON, N.J., Aug. 13, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on
About this update from Soligenix, Inc.
[{"type":"text","content":"PRINCETON, N.J., Aug. 13, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2019.\nChristopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, \"It is an exciting time for Soligenix. We are now approaching data read-out in two Phase 3 clinical programs. We have completed the approximate 90 subject enrollment necessary to support the interim efficacy analysis of our pivotal double-blind, placebo-controlled Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy. This interim analysis, to be conducted by the independent Data Monitoring Committee (DMC) for the trial, is anticipated to occur in September 2019. We expect completion of full enrollment in the study in the second half of 2019, with final top-line results anticipated in the first half of 2020, pending the DMC recommendation.\" \nDr. Schaber continued, \"Following the positive recommendation received from the independent DMC for our pivotal double-blind, placebo-controlled Phase 3 study for the treatment of cutaneous T-cell lymphoma (CTCL) with SGX301 (synthetic hypericin), we continue to enroll patients and anticipate completing study enrollment in the second half of 2019, with final top-line results in the first quarter of 2020.\" \nSoligenix Recent Accomplishments: \nOn July 29, 2019, the Company announced that the European Patent Office had issued two patents, both titled \"Topically Active Steroids for use in Radiation and Chemotherapeutics Injury\". The new patents (#2,373,160 and #2,902,031) claim use of oral beclomethasone 17,21-dipropionate for treatment of damage to the gastrointestinal tract as a result of acute radiation injury, including total body irradiation in an accidental or biodefense context. To view this press release, please click here. On July 8, 2019, the Company announced the appointment of Ms. Diane L. Parks, an accomplished businesswoman and commercial executive with an extensive record of driving profitable growth for large pharmaceutical and biotech...